TrialAnnals of surgical oncology2023

Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.

Qihan Fu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.